Cameron Durrant
2021
In 2021, Cameron Durrant earned a total compensation of $9.7M as Chairman & Chief Executive Officer at KaloBios Pharmaceuticals, a 299% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,039 |
|---|---|
| Option Awards | $8,874,712 |
| Salary | $640,000 |
| Total | $9,717,751 |
Durrant received $8.9M in option awards, accounting for 91% of the total pay in 2021.
Durrant also received $203K in non-equity incentive plan and $640K in salary.
Rankings
In 2021, Cameron Durrant's compensation ranked 1,085th out of 12,415 executives tracked by ExecPay. In other words, Durrant earned more than 91.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,085 out of 12,415 | 91st |
Division Manufacturing | 372 out of 5,505 | 93rd |
Major group Chemicals And Allied Products | 133 out of 2,375 | 94th |
Industry group Drugs | 112 out of 2,096 | 95th |
Industry Pharmaceutical Preparations | 76 out of 1,546 | 95th |
Source: SEC filing on April 12, 2022.
Durrant's colleagues
We found two more compensation records of executives who worked with Cameron Durrant at KaloBios Pharmaceuticals in 2021.